内容概要：人工硬脑膜是用生物材料制成人体脑膜的替代物，用于因颅脑、脊髓损伤、肿瘤及其他颅脑 疾病引起的硬脑膜或脊膜缺损的修补，防止脑脊液外漏、颅内感染、脑膨出、脑粘连和疤痕等严重并发 症，以恢复其完整性。人工硬脑膜属于植介入耗材，伴随着国民可支配收入增加、老龄化程度加深，脑 血管疾病发病率上升，神经外科介入类手术需求增加，推动人工硬脑膜的需求放量增长。但2021年以来 随着集采的稳步推进，国内人工硬脑膜产品价格下降较为明显。2024年，我国人工硬脑膜需求量从2017 年的44.63万片增长至94.61万片，产品价格从2017年的1775元/片下降至800元/片，人工硬脑膜市场规模 则从2020年的10.26亿元下降至2024年的7.57亿元。 关键词：人工硬脑膜行业政策、人工硬脑膜产业链、人工硬脑膜需求量、人工硬脑膜行业均价、人工硬 脑膜市场规模、人工硬脑膜市场竞争格局、人工硬脑膜行业发展趋势 一、人工硬脑膜行业基本概况 神经外科作为医学领域最为复杂的学科之一，是以手术为主要手段，医治中枢神经系统（脑、脊髓）、 周围神经系统和植物神经系统疾病的一门临床外科专科。作为高精尖的前沿学科之一，神经外科对应用 在手术 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2025-052 为进一步加强与投资者的互动交流，冠昊生物科技股份有限公司（以下简称 "公司"）将参加由广东证监局、广东上市公司协会联合举办的"向新提质 价值 领航——2025 年广东辖区投资者集体接待日暨辖区上市公司中报业绩说明会" 活动，现将相关事项公告如下： 本次投资者网上集体接待日活动将采用网络远程的方式举行，投资者可登录 "全景路演"网站（https://rs.p5w.net）参与本次互动交流，活动时间为 2025 年 9 月 19 日（星期五）15:30-17:00。届时公司高管将在线就公司 2025 年中报业绩、 公司治理、发展战略、经营状况和可持续发展等投资者关心的问题，与投资者进 行沟通与交流，欢迎广大投资者踊跃参与。 特此公告。 冠昊生物科技股份有限公司董事会 2025 年 9 月 17 日 冠昊生物科技股份有限公司 关于参加广东辖区 2025 年投资者网上集体接待日暨中报业绩说 明会活动的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 ...

Core Viewpoint - Guanxiao Biological (300238) announced that neither the company nor its controlling subsidiaries provide guarantees to entities outside the scope of consolidated financial statements, nor do they have overdue guarantees, guarantees involved in litigation, or losses due to judgments against guarantees [1] Summary by Relevant Categories - **Company Guarantees** - The company and its controlling subsidiaries do not provide guarantees to any entities outside the consolidated financial statement scope [1] - There are no overdue guarantees reported [1] - **Legal and Financial Standing** - The company is not involved in any litigation related to guarantees [1] - There are no losses incurred from judgments against guarantees [1]

关于全资子公司为公司提供担保的公告 证券代码：300238 证券简称：冠昊生物 公告编号：2025-051 冠昊生物科技股份有限公司 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、担保情况概述 近日，为满足冠昊生物科技股份有限公司(以下简称"公司")经营发展需要， 公司向中国工商银行股份有限公司广州天平架支行申请人民币壹仟万元整 （¥10,000,000.00）银行贷款，公司全资子公司冠昊生命健康科技园有限公司（以 下简称"冠昊科技园"）和广东冠昊再生医学科技开发有限公司（以下简称"再 生医学公司"）为上述贷款提供连带责任保证担保。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等相关规定，本 次担保事项属于上市公司全资子公司为上市公司提供的担保，担保人冠昊科技园 和再生医学公司已分别履行了相应的内部审议程序，无需提交公司董事会或股东 会审议。 二、被担保人的基本情况 公司名称：冠昊生物科技股份有限公司； 统一社会信用代码：91440000707688515X； 成立日期 ...

Group 1 - The company, Guanhao Biological (300238), clarified on September 10 that it is not involved in the brain-computer interface business [1] - The main products related to neurosurgery include biological dura (spinal) membrane patches and type B dura membrane patches [1]

Core Viewpoint - The company, Guanhao Biological (300238.SZ), clarified that it is not involved in the brain-computer interface business, focusing instead on neurosurgical products [1] Group 1: Company Products - The main products related to neurosurgery include biological dura (spinal) membrane patches and type B dura membrane patches [1]

Summary of Key Points Core Viewpoint - Guanhao Biological has experienced a decline in the number of shareholders for the second consecutive period, indicating potential concerns regarding investor confidence and stock performance [2]. Financial Performance - For the first half of the year, the company reported a total revenue of 201 million yuan, representing a year-on-year growth of 5.89% [2]. - The net profit for the same period was approximately 20.4 million yuan, with a year-on-year increase of 1.27% [2]. - The basic earnings per share were recorded at 0.0800 yuan, and the weighted average return on net assets was 3.68% [2]. Shareholder Dynamics - As of August 31, the number of shareholders stood at 28,869, which is a decrease of 2,484 from the previous period (August 20), reflecting a month-on-month decline of 7.92% [2]. - The stock price closed at 16.80 yuan, showing a slight increase of 0.30%, but the cumulative decline since the concentration of shares began is 3.11% [2]. - The stock has experienced 4 days of increases and 4 days of decreases during the reporting period [2].

Core Viewpoint - Guanhao Biological (300238.SZ) reported its semi-annual results for 2025, highlighting a significant presence of institutional investors holding 29.07% of its total shares as of August 27, 2025 [1] Institutional Holdings - A total of 9 institutional investors disclosed their holdings in Guanhao Biological, amounting to 77.0696 million shares, which represents 29.07% of the company's total equity [1] - The institutional holding percentage increased by 0.35 percentage points compared to the previous quarter [1] Public Fund Involvement - Three new public funds were disclosed in this period compared to the previous quarter, including Medical Device ETF, China Securities Index Medical Device ETF, and Ping An CSI 2000 Enhanced Strategy ETF [1] Foreign Investment - One new foreign institution, BARCLAYS BANK PLC, disclosed its holdings this period, while Goldman Sachs LLC was not reported in this quarter [1]

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - There were no changes in the controlling shareholder or actual controller during the reporting period [3] - The company does not have any preferred shareholders or related holdings during the reporting period [3] Group 2 - All directors attended the board meeting that reviewed the report [1] - The company does not require retrospective adjustments or restatements of previous accounting data [2] - There are no significant changes in the number of shareholders or their holdings [2]

冠昊生物科技股份有限公司 第一章 总 则 第一条 为规范冠昊生物科技股份有限公司（以下简称"公司"或"本公司"） 董事、高级管理人员所持公司股份及其变动的管理，维护证券市场秩序，根据《公 司法》《证券法》《上市公司股东减持股份管理暂行办法》《上市公司董事和高级 管理人员所持本公司股份及其变动管理规则》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 《深圳证券交易所上市公司自律监管指引第18号——股东及董事、高级管理人员减 持股份》《深圳证券交易所上市公司自律监管指引第10号——股份变动管理》等法 律法规、规范性文件和《公司章程》有关规定，结合公司实际，制定本制度。 第二条 公司董事、高级管理人员所持本公司股份，是指登记在其名下和利用 他人账户持有的所有本公司股份。 公司董事、高级管理人员从事融资融券交易的，其所持本公司股份还包括记载在 其信用账户内的本公司股份。 董事、高级管理人员所持公司股份及其变动管理制度 第三条 公司董事、高级管理人员在买卖本公司股票及其衍生品种前，应当知 悉《公司法》《证券法》等法律法规、规范性文件中关于内幕交易、操纵市场等 ...